Literature DB >> 6101414

Intravenous cefotaxime in children with bacterial meningitis.

B H Belohradsky, K Bruch, D Geiss, D Kafetzis, W Marget, G Peters.   

Abstract

Thirteen children with meningitis due to Haemophilus influenzae, beta-haemolytic streptococcus group B, Streptococcus pneumoniae, Staphylococcus epidermidis, Neisseria meningitidis, Escherichia coli, or Pseudomonas aeruginosa and who had been unsuccessfully treated with other antibiotics or had causative organisms which were resistant to available antibiotics were treated with intravenous cefotaxime. Nine children were cured; in one case infection (with a different organism) recurred but a further course of cefotaxime was successful; one child died, with sterile CSF; one child died from his underlying disease (astrocytoma); and one child was cured with sequelae (hydrocephalus). A further child with meningitis caused by E. coli had been treated unsuccessfully by intravenous and intraventricular chloramphenicol and gentamicin; intravenous and intraventricular cefotaxime was successful. The agent was well tolerated. CSF levels were measured in seven children and ranged from 300 to 27 200 microgram/l; published and unpublished in-vitro studies suggest that minimum inhibitory concentrations for cefotaxime against the organisms commonly causing bacterial meningitis are usually well below 250 microgram/l.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6101414     DOI: 10.1016/s0140-6736(80)90491-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

Review 1.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

2.  Cefotaxime versus chloramphenicol for ampicillin-resistant Haemophilus influenzae meningitis. A retrospective study of 62 cases.

Authors:  J R Lapointe; L Chicoine
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Cefotaxime in pneumococcal meningitis.

Authors:  H Lecour; A Seara; A M Miranda; J Cordeiro
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  Cefotaxime monotherapy of bacterial meningitis caused by gram-positive pathogens.

Authors:  H F Helwig
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Comparison of ceftriaxone and traditional therapy of bacterial meningitis.

Authors:  B L Congeni
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 6.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

7.  In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.

Authors:  S Shelton; J D Nelson; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

8.  Cephalosporins: recent developments.

Authors:  A Kumar
Journal:  J Natl Med Assoc       Date:  1983-02       Impact factor: 1.798

9.  Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.

Authors:  R Nau; H W Prange; P Muth; G Mahr; S Menck; H Kolenda; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

10.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.